These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21627335)

  • 1. Administration of CREON® pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study.
    Shlieout G; Koerner A; Maffert M; Forssmann K; Caras S
    Clin Drug Investig; 2011; 31(7):e1-7. PubMed ID: 21627335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic enzymes prepared in bicarbonate solution for administration through enteral feeding tubes.
    Boullata AM; Boullata JI
    Am J Health Syst Pharm; 2015 Jul; 72(14):1210-4. PubMed ID: 26150571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a Creon delayed-release pancreatic enzyme protocol for clearing occluded enteral feeding tubes.
    Stumpf JL; Kurian RM; Vuong J; Dang K; Kraft MD
    Ann Pharmacother; 2014 Apr; 48(4):483-7. PubMed ID: 24436458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes.
    Clark AM; Pellock JM; Holmay M; Anders B; Cloyd J
    Epilepsy Behav; 2016 Apr; 57(Pt A):105-110. PubMed ID: 26943947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.
    Kuhn RJ; Eyting S; Henniges F; Potthoff A
    J Pediatr Pharmacol Ther; 2007 Apr; 12(2):115-28. PubMed ID: 23055848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
    Kuhn RJ; Gelrud A; Munck A; Caras S
    Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding.
    Wells KA; Losin WG
    Clin Ther; 2008 Jul; 30(7):1300-8. PubMed ID: 18691989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
    Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
    Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
    Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
    Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
    Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
    Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of the gastrointestinal delivery of acid-sensitive pancrelipase in a next generation enteric capsule using an exocrine pancreatic insufficiency disease model.
    Jannin V; Duysburgh C; Gonzalez V; Govaert M; Agisson M; Marzorati M; Madit N
    Int J Pharm; 2023 Jan; 630():122441. PubMed ID: 36442722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a Viokace Pancreatic Enzyme Protocol for Clearing Occluded Enteral Feeding Tubes: A Quality Assurance Evaluation.
    Kurish HP; Gabriel JM; Bruck CL; Stumpf JL
    J Pharm Pract; 2023 Apr; 36(2):271-275. PubMed ID: 34340577
    [No Abstract]   [Full Text] [Related]  

  • 15. A systematic approach for assessing the suitability of enteral feeding tubes for the administration of controlled-release pellet formulations.
    Karkossa F; Lehmann N; Klein S
    Int J Pharm; 2022 Jan; 612():121286. PubMed ID: 34775043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme content and acid stability of enteric-coated pancreatic enzyme products in vitro.
    Case CL; Henniges F; Barkin JS
    Pancreas; 2005 Mar; 30(2):180-3. PubMed ID: 15714141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.
    Aloulou A; Puccinelli D; Sarles J; Laugier R; Leblond Y; Carrière F
    Aliment Pharmacol Ther; 2008 Feb; 27(3):283-92. PubMed ID: 17973644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The enzyme levels in blood are not affected by oral administration of a pancreatic enzyme preparation (Creon 10,000) in pancreas-insufficient pigs.
    Gewert K; Holowachuk SA; Rippe C; Gregory PC; Erlanson-Albertsson C; Olivecrona G; Kruszewska D; Piedra JV; Weström B; Pierzynowski SG
    Pancreas; 2004 Jan; 28(1):80-8. PubMed ID: 14707735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
    Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
    Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro studies of microsphere pancreatic supplements.
    Littlewood JM; Kelleher J; Walters MP; Johnson AW
    J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S22-9. PubMed ID: 2457072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.